Phase II study of combination chemotherapy of gemcitabine, TS-1 and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2016
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Nafamostat (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 02 Jul 2016 Status changed from recruiting to active, no longer recruiting, according to the results published.
- 15 Aug 2011 New trial record